Derms on Drugs

Three papers, three very different reactions: a Treg-boosting AD drug that may be too clever for its own good, a Steri-Strip trick you can use tomorrow, and Rinvoq alopecia data that have the Derms calling game changer.

Convince the Derms on Drugs makes its debut with Dr. Christopher Sayed making the case for earlier systemic treatment in HS. Can he convince the Derms to act before recurring lesions become tunnels, scars, and damage no medication can undo?

Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hiding in your patient’s shampoo.

Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clot risk may depend on the disease.

Male genital disease expert Dr. Christopher Bunker joins the Derms for the penis episode no one else was brave enough to make. Lichen sclerosus, circumcision, penile cancer—and one diagnosis he says doesn’t exist—are all on the table.

The Derms debut a shorter format with three papers and one newly dirt-cheap drug: generic tofacitinib. The safety, the risks, and the practicalities—right down to getting it for just $25 a month.

Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections, and make the case for treating molluscum sooner. Plus, how to recognize measles—and why its most frightening complication may not appear for years.

The CSU rulebook is getting a rewrite, and the Derms on Drugs crew has thoughts. Dr. Jason Hawkes joins the conversation to talk new guidelines, new therapies, and why it may be time to stop sending these patients somewhere else.

This week, the DoD tackle studies that leave plenty of room for debate—from skin cancer treatment costs and melanoma risk to HS, alopecia areata, and the real-world decisions that don't always come with straightforward answers.

The DOD tackle longitudinal melanonychia, retronychia, nail biopsies, and other everyday nail problems—with enough practical pearls to make you rethink your next nail patient.

One paper questions melanoma screening. Another challenges patch testing. By the end, the conversation has wandered into studies on physician burnout and more, sparking exactly the kind of debate you'd expect from DoD.

Dermatologist William Damsky, MD, joins the DoD crew to explore immune biomarkers, treatment prediction, and whether precision dermatology is finally ready for prime time.

Burnout isn't just about long hours. From moral distress to prior authorizations and system barriers, this week's conversation with Dr. Lisa Swanson explores what's really wearing physicians down—and why resilience alone won't fix it.

Thin melanomas that behave badly, a surprisingly intriguing role for oxybutynin in HS, and a reminder that some of dermatology’s most trusted assumptions deserve a second look. This week’s 6-pack is all about the exceptions that force us to rethink the rules.

The diagnoses get messy, the treatment decisions get interesting, and the DoD crew has opinions. From a major scabies study to a practical overlap-disease pearl, this week's episode is full of reminders that dermatology is rarely as straightforward as it seems.

An emerging infection out of France, a surprisingly clever vitiligo combo, and a spirited debate about whether medicine has ever actually cured anything. Just another normal week on Derms on Drugs.

Melanoma, Anxiety, and Depression Links; Biosimilars vs Humira; Air Pollution and Atopic Dermatitis – Have We Finally Figured Out Why Eczema Is So Common and much, much more… Which patients are the most affected by anxiety and depression after a melanoma diagnosis and what can we do about it? Patients who are switched onto a biosimilar do “worse” than patients who start one as their first therapy – why? We finally got eczema answers. Turns out that air pollution, both indoor and outdoor, is the cause of the atopic dermatitis epidemic that started in the 1970s and is why eczema is more common in urban areas. Ian Myles explains how he proved that air pollution is the driving force behind atopic dermatitis and helps our team understand what it all means Plus: Predictors of acne relapse after isotretinoin, dupilumab prevents cancer, how well does tralokinumab work in dupilumab "failures," ferulic acid for rosacea, cysteamine vs hydroquinone for melasma, and the best way to treat digital mucous cysts Guest: Ian A. Myles, MD, Mph Dr. Myles, Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. He worked under the mentorship of Dr. Sandip Datta investigating the mechanistic details of susceptibility to S. aureus skin infections. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. LCDR Myles has supported several USPHS missions, from the Ebola virus vaccine trial in West Africa to congressional Gold Medal Ceremonies at the U.S. Capitol. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs.

Psoriatic arthritis usually gets explained in a way that makes derms want to leave the room. Not this episode. Drs. Zirwas, Ferris, and Patton are joined by double-boarded rheum-derm expert Dr. Saakshi Khattri for a practical, entertaining deep dive into recognizing PsA and making smarter treatment decisions — without the rheumatology overload.

This week’s Derms on Drugs is a classic six-pack episode. From cutting-edge CTCL therapies to biologic safety data and the growing world of oral photoprotection, the group covers the studies worth knowing—plus a few opinions spicy enough to start a conference hallway argument.

This week on Derms on Drugs, the gang goes deep into vulvar dermatology with double-boarded derm/OB-GYN expert Dr. Kelly Tyler. From lichen sclerosus and recurrent candidiasis to estrogen, lasers, PRP, and the wildly overmarketed “Mona Lisa” treatments, they they break down what helps, what doesn’t, and what’s probably paying for someone’s boat. Equal parts practical pearls and inappropriate laughter — exactly how medical education should be.